MetaCap

Aptevo Therapeutics (APVO) vs Artelo Biosciences (ARTL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aptevo Therapeutics is the larger company by market cap ($1.4 million vs $1.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APVO-78.04%ARTL-59.24%
+4%-39%-82%
Oct 7, 20261 yearNov 20, 2026
APVO-77.42%ARTL-57.36%
+4%-39%-81%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APVO versus ARTL key metrics
MetricAPVOARTL
Share price$0.4041$1.39
Market cap$1.40M$1.30M
1-day change-2.37%-4.14%
P/E ratio (TTM)0.01—
EPS (TTM)$66.96$-20.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-25.97M$-12.88M
52-week high$25.56$179.19
52-week low$0.377$1.30
Distance from 52-week high-98.42%-99.22%
Analyst consensusnone—
Avg. price target upside+6210.32%—
Average volume132.90K476.69K
Shares outstanding3.46M937.18K
Employees337
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aptevo Therapeutics

APVO stock →

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About Artelo Biosciences

ARTL stock →

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

APVO vs ARTL FAQ

Which is bigger, Aptevo Therapeutics or Artelo Biosciences?

Aptevo Therapeutics (APVO) is larger, with a market capitalization of $1.40M compared with $1.30M for Artelo Biosciences (ARTL).

Are Aptevo Therapeutics and Artelo Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons